错配修复缺陷表型在上尿路尿路上皮癌根治性肾输尿管切除术患者中的预后与预测价值
本研究基于法国多中心281例接受根治性肾输尿管切除术的上尿路尿路上皮癌患者,回顾性评估错配修复缺陷(dMMR)表型的预后与预测价值。结果显示dMMR表型是延长无复发生存、癌特异性生存和总生存的独立预测因素,且与辅助化疗疗效存在显著交互作用。dMMR患者辅助化疗无显著获益,非dMMR患者辅助化疗显著延长生存。
要点
- dMMR表型是UTUC患者预后良好的独立预测因素。
- 辅助化疗仅使非dMMR患者显著获益,dMMR患者无显著获益。
- dMMR表型与PD-L1和PD-1低表达显著相关。
核心结论
- dMMR表型与UTUC患者 favorable 病理特征和预后相关,但导致辅助化疗敏感性降低及PD-L1/PD-1表达下降。
研究设计与样本
- 回顾性多中心研究,纳入2000至2015年法国十家医院281例接受根治性肾输尿管切除术的UTUC患者。
- 采用2-mm芯组织微阵列免疫组化检测dMMR表型及PD-L1、PD-1表达。
- 多变量Cox回归模型评估dMMR对RFS、CSS、OS的影响,并用交互项检验辅助化疗疗效异质性。
- 多变量逻辑回归模型评估dMMR对PD-L1和PD-1表达的影响。
主要发现
- 76例(27.0%)患者为dMMR表型。
- dMMR是延长RFS的独立预测因素(HR=0.41;95%CI=[0.21-0.83];p=0.01)。
- dMMR是延长CSS的独立预测因素(HR=0.38;95%CI=[0.18-0.83];p=0.02)。
- dMMR是延长OS的独立预测因素(HR=0.44;95%CI=[0.22-0.89];p=0.02)。
- 多变量Cox模型中dMMR与辅助化疗使用存在显著交互作用(所有pinteraction<0.05)。
关键数值与推荐
- 亚组分析:非dMMR患者中辅助化疗显著延长RFS(HR=0.14;95%CI=[0.06-0.30];p<0.001)。
- 非dMMR患者中辅助化疗显著延长CSS(HR=0.10;95%CI=[0.03-0.29];p<0.001)。
- 非dMMR患者中辅助化疗显著延长OS(HR=0.23;95%CI=[0.10-0.54];p=0.001)。
- dMMR患者中辅助化疗无显著获益(所有p>0.05)。
- 多变量逻辑回归:dMMR与PD-L1低表达相关(OR=0.20;95%CI=[0.10-0.80];p=0.001),与PD-1低表达相关(OR=0.36;95%CI=[0.16-0.79];p=0.01)。
临床怎么用
- dMMR表型可用于UTUC患者风险分层和预后评估。
- 非dMMR患者可能从辅助化疗中显著获益,dMMR患者辅助化疗无显著获益。
- dMMR表型与PD-L1/PD-1低表达相关,可能影响免疫治疗策略。
局限性
- 回顾性多中心研究设计。
- 样本量281例,dMMR亚组76例。
- 免疫组化基于2-mm芯组织微阵列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Given the conflicting evidence currently available in the literature, our aim was to assess the prognostic and predictive values of the deficient mismatch repair (dMMR) phenotype in a large cohort of upper tract urothelial carcinoma (UTUC) patients. METHODS: Based on our national network, we performed a retrospective multicenter study including 281 UTUC patients treated with radical nephroureterectomy between 2000 and 2015 at ten French hospitals. The dMMR phenotype as well as PD-L1 and PD-1 expression were determined using immunohistochemistry analyses based on 2-mm-core tissue microarrays. Multivariable Cox regression models were fitted to assess the impact of the dMMR phenotype on recurrence-free (RFS), cancer-specific (CSS), and overall (OS) survival using interaction terms to test the heterogeneity of the treatment effect of adjuvant chemotherapy (AC). Multivariable logistic regression models were also fitted to assess the impact of the dMMR phenotype on PD-L1 and PD-1 expression. KEY FINDINGS AND LIMITATIONS: Overall, 76 (27.0%) patients had a dMMR phenotype, which was an independent predictor of prolonged RFS (hazard ratio [HR] = 0.41; 95% confidence interval [CI] = [0.21-0.83]; p = 0.01), CSS (HR = 0.38; 95% CI = [0.18-0.83]; p = 0.02), and OS (HR = 0.44; 95% CI = [0.22-0.89]; p = 0.02), with a significant interaction with the use of AC in multivariable Cox regression models (all pinteraction < 0.05). Subgroup analyses showed that the use of AC was significantly associated with prolonged RFS (HR = 0.14; 95% CI = [0.06-0.30]; p < 0.001), CSS (HR = 0.10; 95% CI = [0.03-0.29]; p < 0.001), and OS (HR = 0.23; 95% CI = [0.10-0.54]; p = 0.001) in non-dMMR patients only, without any significant benefit in dMMR patients (all p > 0.05). In multivariable logistic regression analyses, the dMMR phenotype was significantly associated with inverse PD-L1 (OR = 0.20; 95% CI = [0.10-0.80]; p = 0.001) and PD-1 (OR = 0.36; 95% CI = [0.16-0.79]; p = 0.01) expression. CONCLUSIONS AND CLINICAL IMPLICATIONS: We observed that the dMMR phenotype was associated with favorable pathological characteristics and prognosis in UTUC patients, despite conferring decreased sensitivity to AC and lower PD-L1 or PD-1 expression.
引用
- Gabriel PE, Compérat E, Cancel-Tassin G, et al. Assessment of the Prognostic and Predictive Values of the Deficient Mismatch Repair Phenotype in Patients Treated with Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2025. PMID: 40307090. doi:10.1016/j.euo.2025.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。